Novartis AG Form 6-K Summary: Second Quarter 2011
Business Context and Reporting Period
This Form 6-K reports the unaudited financial results for Novartis AG for the second quarter and first half ended June 30, 2011. The reporting period reflects the full consolidation of Alcon, Inc., following the merger completed on April 8, 2011. The Group operates across five divisions: Pharmaceuticals, Alcon, Sandoz, Vaccines & Diagnostics, and Consumer Health.
Key Financial Metrics
| Metric | Q2 2011 (USD m) | Q2 2010 (USD m) | H1 2011 (USD m) | H1 2010 (USD m) |
|---|---|---|---|---|
| Net Sales | 14,915 | 11,716 | 28,942 | 23,847 |
| Operating Income | 3,322 | 2,961 | 6,730 | 6,472 |
| Net Income | 2,726 | 2,437 | 5,547 | 5,385 |
| EPS (USD) | 1.13 | 1.06 | 2.33 | 2.34 |
| Free Cash Flow | 3,297 | 2,368 | 4,919 | 5,271 |
| Net Debt (as of June 30) | 21,901 | 14,853 (Dec 31, 2010) | - | - |
Core Results (Non-IFRS): Core operating income for Q2 2011 was USD 4.2 billion (up 29% reported, 30% constant currency). Core EPS for Q2 2011 was USD 1.48 (up 23% reported, 25% constant currency).
Material Changes vs. Prior Period
- Sales Growth: Net sales grew 27% (19% in constant currencies) in Q2 2011, driven by the full consolidation of Alcon, strong volume growth in Pharmaceuticals and Sandoz, and favorable currency impacts (+8%).
- Profitability: Operating income rose 12% (15% cc). Core operating margin improved by 0.4 percentage points to 28.4% in Q2, despite currency headwinds.
- Divisional Performance:
- Pharmaceuticals: Sales up 10% (2% cc); growth driven by recently launched products (28% of sales) offsetting generic competition.
- Alcon: Pro forma sales up 12% (6% cc); strong growth in emerging markets and ophthalmic pharmaceuticals.
- Sandoz: Sales up 25% (16% cc); driven by volume growth and biosimilars, offset by price erosion.
- Vaccines & Diagnostics: Sales declined 47% (50% cc) primarily due to the absence of A(H1N1) pandemic flu vaccine sales recorded in Q2 2010.
- Exceptional Items: Q2 operating income included a USD 324 million gain from the Elidel divestment, offset by impairment charges (USD 169 million) and legal provisions (USD 150 million in Sandoz).
Guidance, Outlook, and Risks
- 2011 Outlook: Group constant currency sales growth is expected to be around the double-digit mark. Pharmaceuticals is expected to deliver low- to mid-single digit growth; Alcon mid- to high-single digit; Sandoz mid- to high-single digit.
- Margin Expectations: Management expects to improve constant currency core operating income margin while absorbing price cuts and generic competition.
- Currency Impact: If June average exchange rates prevail, the full-year impact is expected to be positive (+5%) on sales and negative (-3%) on operating income.
- Capital Structure: The Board removed the restriction limiting dividend payments to 35-60% of net income. Net debt increased to USD 21.9 billion due to dividend payments and Alcon-related share repurchases. Credit rating remains double-A.
- Risks: Key risks include regulatory delays, clinical trial outcomes, patent expirations (e.g., Diovan, Femara), legal proceedings (Zometa/Aredia, AWP litigation), and integration challenges with Alcon.
Investor Verification Checklist
- Alcon Integration: Verify the realization of synergies and the impact of Alcon's full consolidation on future margins and R&D spend.
- Patent Cliffs: Monitor sales trends for Diovan and Femara as generic competition intensifies in key markets.
- Vaccines Volatility: Assess the sustainability of Vaccines & Diagnostics revenue excluding the one-time A(H1N1) pandemic sales.
- Legal Provisions: Track the status of the Sandoz AWP litigation and Zometa/Aredia product liability cases for potential future charges.
- Net Debt Trajectory: Review the company's ability to reduce net debt given the recent increase to USD 21.9 billion and ongoing share repurchase programs.